Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dennis A. Eichenauer, Andreas Engert, M. André, et al.
Annals of Oncology (2014) Vol. 25, pp. iii70-iii75
Open Access | Times Cited: 455

Showing 1-25 of 455 citing articles:

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 27, pp. 3048-3058
Open Access | Times Cited: 1474
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Ralph M. Meyer, Mary Gospodarowicz, Joseph M. Connors, et al.
New England Journal of Medicine (2011) Vol. 366, Iss. 5, pp. 399-408
Open Access | Times Cited: 397
Cardiac Complications of Thoracic Irradiation
Catherine Jaworski, Justin A. Mariani, Greg Wheeler, et al.
Journal of the American College of Cardiology (2013) Vol. 61, Iss. 23, pp. 2319-2328
Closed Access | Times Cited: 362
Antibody–drug conjugates come of age in oncology
Charles Dumontet, Janice M. Reichert, Peter D. Senter, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 641-661
Closed Access | Times Cited: 354
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma
Tarec Christoffer El‐Galaly, Francesco d’Amore, Karen Juul Mylam, et al.
Journal of Clinical Oncology (2012) Vol. 30, Iss. 36, pp. 4508-4514
Open Access | Times Cited: 281
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes, Anna Sureda, Dina Ben‐Yehuda, et al.
Journal of Clinical Oncology (2012) Vol. 30, Iss. 18, pp. 2197-2203
Closed Access | Times Cited: 257
Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
Cindy Strehl, Lisa Ehlers, Timo Gaber, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 243
Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative
Athan Baillet, Laure Gossec, Loreto Carmona, et al.
Annals of the Rheumatic Diseases (2016) Vol. 75, Iss. 6, pp. 965-973
Closed Access | Times Cited: 217
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne‐Ségolène Cottereau, Annibale Versari, Annika Loft, et al.
Blood (2018) Vol. 131, Iss. 13, pp. 1456-1463
Open Access | Times Cited: 162
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
Paul J. Bröckelmann, Helen Goergen, Ulrich Keller, et al.
JAMA Oncology (2020) Vol. 6, Iss. 6, pp. 872-872
Open Access | Times Cited: 147
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Peter Borchmann, Annette Plütschow, Carsten Kobe, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 2, pp. 223-234
Closed Access | Times Cited: 134
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients
Michel Meignan, Myriam Sasanelli, Olivier Casasnovas, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2014) Vol. 41, Iss. 6, pp. 1113-1122
Closed Access | Times Cited: 170
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
Salim Kanoun, Cédric Rossi, Alina Berriolo-Riedinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2014) Vol. 41, Iss. 9, pp. 1735-1743
Closed Access | Times Cited: 168
Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?
Hugo J.A. Adams, Thomas C. Kwee, Bart de Keizer, et al.
Annals of Oncology (2013) Vol. 25, Iss. 5, pp. 921-927
Open Access | Times Cited: 127
Value of18F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies
Lebriz Uslu, Jessica Donig, Michael P. Link, et al.
Journal of Nuclear Medicine (2015) Vol. 56, Iss. 2, pp. 274-286
Open Access | Times Cited: 112
FDG‐PET/CT in the management of lymphomas: current status and future directions
Tarec Christoffer El‐Galaly, Diego Villa, Lars Christian Gormsen, et al.
Journal of Internal Medicine (2018) Vol. 284, Iss. 4, pp. 358-376
Open Access | Times Cited: 112
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Lesley J. Scott
Drugs (2017) Vol. 77, Iss. 4, pp. 435-445
Open Access | Times Cited: 107
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Boris Böll, Helen Goergen, Karolin Behringer, et al.
Blood (2016) Vol. 127, Iss. 18, pp. 2189-2192
Open Access | Times Cited: 106
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines
Andrew Wirth, N. George Mikhaeel, Berthe M.P. Aleman, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 107, Iss. 5, pp. 909-933
Open Access | Times Cited: 105
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Ramón García‐Sánz, Anna Sureda, Fátima De la Cruz, et al.
Annals of Oncology (2019) Vol. 30, Iss. 4, pp. 612-620
Open Access | Times Cited: 103
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group
Dennis A. Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 26, pp. 2857-2862
Closed Access | Times Cited: 95
EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part II
Paul S. Sidhu, Knut Brabrand, Vito Cantisani, et al.
Ultraschall in der Medizin - European Journal of Ultrasound (2015) Vol. 36, Iss. 06, pp. E15-E35
Open Access | Times Cited: 95
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis
Siew Lian Leong, Nathorn Chaiyakunapruk, Shaun Wen Huey Lee
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 92
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric18F-FDG PET/CT for Oncology 1.0
Reza Vali, Adam Alessio, René Balza, et al.
Journal of Nuclear Medicine (2020) Vol. 62, Iss. 1, pp. 99-110
Open Access | Times Cited: 82
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Marie José Kersten, Julia Driessen, Josée M. Zijlstra, et al.
Haematologica (2020) Vol. 106, Iss. 4, pp. 1129-1137
Open Access | Times Cited: 81
Page 1 - Next Page

Scroll to top